Some studies sponsored by Novo Nordisk suggest that semaglutide may actually help reduce the risk of kidney disease over the long term. But there have also been reports of individuals taking GLP-1 ...

Novo Nordisk has shared positive headline results from a late-stage study evaluating a higher dose of its GLP-1 receptor agonist semaglutide in adults with obesity. The phase 3b STEP UP trial has been ...

The recalled drugs comprised semaglutide, which belongs to the GLP-1 class of drugs, and pyridoxine ... company says Ozempic maker Novo Nordisk says it’s the only company in Canada with Health ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...

Semaglutide could help people drink less alcohol. Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help people drink less ...

You should inject semaglutide subcutaneously, that is, just under the surface of your skin. You can rotate injections between your stomach, upper arm, and thigh. Semaglutide is a prescription type ...

The 'Semaglutide and cardiovascular outcomes in obesity without diabetes' (SELECT) trial, funded by Novo Nordisk, is considered to be the largest and longest clinical trial to evaluate the effects ...

once-weekly semaglutide 2.4 mg (Wegovy, Novo Nordisk) or placebo along with lifestyle intervention for 72 weeks. The trial’s primary outcome was superiority in weight loss with semaglutide 7.2 ...

Competition from Him & Hers Health seems to be weighing on Novo Nordisk's stock ... a small study that suggests that "low doses" of semaglutide (the active ingredient in Ozempic) may be helpful ...

The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol intake, according to new research led by Christian ...